Kulkarni Samarth 4

What Happened Samarth Kulkarni, CEO of CRISPR Therapeutics (CRSP), reported conversion/exercise of derivative awards and a subsequent sale. The Form 4 shows a conversion/exercise of 13,250 derivative units on Feb 18, 2026, and an open-market sale of 6,967 shares on Feb 19, 2026 at $52.58 each, generating proceeds of $366,325. The filing also reports a same-day derivative disposition of 13,250 units (see Key Details for notes).

Key Details

• Filing date / Period of report: Filed 2026-02-20 for transactions on 2026-02-18 and 2026-02-19 (filed within the typical 2-business-day window).
• Transactions:
  • 2026-02-18: Exercise/conversion of derivative (code M) — 13,250 shares (acquired).
  • 2026-02-18: Disposition of 13,250 derivative units (code M) — reported as disposed.
  • 2026-02-19: Open-market sale (code S) — 6,967 shares at $52.58 each = $366,325 total.
• Shares owned after transaction: Not specified in the supplied excerpt of the filing.
• Footnotes of note:
  • F1: Each RSU converts to one common share.
  • F3: The 6,967-share sale reflects shares sold to cover tax withholding on vesting (mandated by the company’s RSU Settlement Policy) — not a discretionary sale.
  • F2/F4: Filing reflects prior transfers (85,622 shares from a 2023 GRAT) and the RSU award granted Feb 18, 2022 that vested in quarterly tranches culminating on Feb 18, 2026.

Context

• The filing indicates conversion/exercise of derivative awards concurrent with RSU vesting; part of the resulting shares were sold to meet tax withholding obligations (per company policy), which is routine and non-discretionary.
• Sales to cover taxes or withholding are common after vesting and do not necessarily signal management’s view of the stock.